These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 32333154

  • 1. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis.
    Yoon SE, Kim SJ, Yoon DH, Koh Y, Mun YC, Do YR, Choi YS, Yang DH, Kim MK, Lee GW, Suh C, Ko YH, Kim WS.
    Ann Hematol; 2020 Jun; 99(6):1283-1291. PubMed ID: 32333154
    [Abstract] [Full Text] [Related]

  • 2. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
    Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, Belada D, Samoilova O, Suh C, Leppä S, Rai S, Turgut M, Jurczak W, Cheung MC, Gurion R, Yeh SP, Lopez-Hernandez A, Dührsen U, Thieblemont C, Chiattone CS, Balasubramanian S, Carey J, Liu G, Shreeve SM, Sun S, Zhuang SH, Vermeulen J, Staudt LM, Wilson W, PHOENIX investigators.
    J Clin Oncol; 2019 May 20; 37(15):1285-1295. PubMed ID: 30901302
    [Abstract] [Full Text] [Related]

  • 3. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, Hivert B, Westin J, Vermeulen J, Bandyopadhyay N, de Vries R, Balasubramanian S, Hellemans P, Smit JW, Fourneau N, Oki Y.
    Lancet Oncol; 2014 Aug 20; 15(9):1019-26. PubMed ID: 25042202
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402.
    Witzig TE, Hong F, Micallef IN, Gascoyne RD, Dogan A, Wagner H, Kahl BS, Advani RH, Horning SJ.
    Br J Haematol; 2015 Sep 20; 170(5):679-86. PubMed ID: 25974212
    [Abstract] [Full Text] [Related]

  • 6. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
    Hong JY, Ryu KJ, Park C, Hong M, Ko YH, Kim WS, Kim SJ.
    Oncotarget; 2017 Feb 21; 8(8):13782-13791. PubMed ID: 28099151
    [Abstract] [Full Text] [Related]

  • 7. Detection of the Incidence of Infections and Acute Biochemical Changes in Diffused Large B-Cell Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) with and without Rituximab.
    Ali K, Sial AA, Baig MT, Ansari SH, Adil SO, Shamsi TS.
    Curr Drug Saf; 2018 Feb 21; 13(2):102-106. PubMed ID: 29564988
    [Abstract] [Full Text] [Related]

  • 8. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabeçadas J, Salles G, Gaulard P, Bosly A, Coiffier B.
    J Clin Oncol; 2017 Aug 01; 35(22):2473-2481. PubMed ID: 28426350
    [Abstract] [Full Text] [Related]

  • 9. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
    Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, Viardot A, Soekler M, Keller U, Schmidt C, Truemper L, Mahlberg R, Marks R, Hoeffkes HG, Metzner B, Dierlamm J, Frickhofen N, Haenel M, Neubauer A, Kneba M, Merli F, Tucci A, de Nully Brown P, Federico M, Lengfelder E, di Rocco A, Trappe R, Rosenwald A, Berdel C, Maisenhoelder M, Shpilberg O, Amam J, Christofyllakis K, Hartmann F, Murawski N, Stilgenbauer S, Nickelsen M, Wulf G, Glass B, Schmitz N, Altmann B, Loeffler M, Pfreundschuh M, FLYER Trial Investigators, German Lymphoma Alliance.
    Lancet; 2019 Dec 21; 394(10216):2271-2281. PubMed ID: 31868632
    [Abstract] [Full Text] [Related]

  • 10. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D.
    Lancet; 2013 May 25; 381(9880):1817-26. PubMed ID: 23615461
    [Abstract] [Full Text] [Related]

  • 11. Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.
    Ozsan N, Cagirgan S, Saydam G, Gunes A, Hekimgil M.
    Pathol Res Pract; 2013 Aug 25; 209(8):471-8. PubMed ID: 23726928
    [Abstract] [Full Text] [Related]

  • 12. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
    Beltran BE, Quiñones P, Morales D, Malaga JM, Chavez JC, Sotomayor EM, Castillo JJ.
    Hematol Oncol; 2018 Feb 25; 36(1):93-97. PubMed ID: 28639256
    [Abstract] [Full Text] [Related]

  • 13. Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.
    Ok CY, Li L, Xu-Monette ZY, Visco C, Tzankov A, Manyam GC, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Chen J, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ai W, Ponzoni M, Ferreri AJ, Farnen JP, Møller MB, Bueso-Ramos CE, Miranda RN, Winter JN, Piris MA, Medeiros LJ, Young KH.
    Clin Cancer Res; 2014 May 01; 20(9):2338-49. PubMed ID: 24583797
    [Abstract] [Full Text] [Related]

  • 14. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.
    Lancet Oncol; 2017 Aug 01; 18(8):1076-1088. PubMed ID: 28668386
    [Abstract] [Full Text] [Related]

  • 15. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial.
    Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, Nagai H, Takizawa J, Fukuhara N, Nagafuji K, Miyazaki K, Ohtsuka E, Okamoto M, Sugita Y, Uchida T, Kayukawa S, Wake A, Ennishi D, Kondo Y, Izumi T, Kin Y, Tsukasaki K, Hashimoto D, Yuge M, Yanagisawa A, Kuwatsuka Y, Shimada S, Masaki Y, Niitsu N, Kiyoi H, Suzuki R, Tokunaga T, Nakamura S, Kinoshita T.
    Lancet Oncol; 2020 Apr 01; 21(4):593-602. PubMed ID: 32171071
    [Abstract] [Full Text] [Related]

  • 16. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
    Shin HJ, Chung JS, Song MK, Kim SK, Choe S, Cho GJ.
    Cancer Chemother Pharmacol; 2012 May 01; 69(5):1165-72. PubMed ID: 22215473
    [Abstract] [Full Text] [Related]

  • 17. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era.
    Sato A, Nakamura N, Kojima M, Ohmachi K, Carreras J, Kikuti YY, Numata H, Ohgiya D, Tazume K, Amaki J, Moriuchi M, Miyamoto M, Aoyama Y, Kawai H, Ichiki A, Hara R, Kawada H, Ogawa Y, Ando K.
    Cancer Sci; 2014 Sep 01; 105(9):1170-5. PubMed ID: 24974976
    [Abstract] [Full Text] [Related]

  • 18. How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience.
    Huang BT, Zeng QC, Yu J, Xiao Z, Li BS, Zhang CL, Ji HB.
    J Cancer Res Clin Oncol; 2012 Jan 01; 138(1):125-32. PubMed ID: 22057732
    [Abstract] [Full Text] [Related]

  • 19. Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
    Li X, Huang H, Xu B, Guo H, Lin Y, Ye S, Yi J, Li W, Wu X, Wang W, Zhan H, Xie D, Peng J, Cao Y, Pu X, Guo C, Hong H, Wang Z, Fang X, Zhou Y, Lin S, Liu Q, Lin T.
    Cancer Res Treat; 2019 Jul 01; 51(3):919-932. PubMed ID: 30282447
    [Abstract] [Full Text] [Related]

  • 20. Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial.
    Melani C, Dowdell K, Pittaluga S, Dunleavy K, Roschewski M, Song JY, Calattini S, Kawada JI, Price DA, Chattopadhyay PK, Roederer M, Lucas AN, Steinberg SM, Jaffe ES, Cohen JI, Wilson WH.
    Lancet Haematol; 2023 May 01; 10(5):e346-e358. PubMed ID: 37011643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.